Arbutus Biopharma (ABUS) Amortization of Goodwill (2019)

Arbutus Biopharma (ABUS) posted quarterly Amortization of Goodwill of $29000.0 for Q4 2019, down 99.87% on a QoQ basis from $22.5 million in Q3 2019.

Arbutus Biopharma (ABUS) Amortization of Goodwill (2019) Analysis & Trends

Arbutus Biopharma (ABUS) has reported Amortization of Goodwill for 1 consecutive years, with $29000.0 the latest figure, recorded in Q4 2019.

  • Quarterly Amortization of Goodwill changed N/A year-over-year to $29000.0 in Q4 2019, while the trailing twelve-month figure through Dec 2020 was $22.5 million (changed 0.0% YoY) and the FY2019 annual result came in at $22.5 million, changed N/A from the prior year.
  • Amortization of Goodwill retreated to $29000.0 in Q4 2019 per ABUS's latest filing, from $22.5 million in the prior quarter.
  • Over the last five years, Amortization of Goodwill for ABUS reached as high as $22.5 million in Q3 2019 and fell as low as $29000.0 in Q4 2019.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Arbutus Biopharma 880.36 Mn 785.13 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2019 29,000.00
Dec 31, 2019 29,000.00
Sep 30, 2019 22.47 Mn
Sep 30, 2019 22.47 Mn